IGI Laboratories, Inc. To Manufacture Commercial Pharmaceutical Prescription Products

BUENA, N.J., (BUSINESS WIRE) -- IGI LABORATORIES, INC. (IG: IG1.82, -0.03, -1.6%) a premier global provider of skin treatment products will begin manufacturing, filling, and packaging commercial prescription products for a new pharmaceutical customer. The two topical prescription products are indicated for the removal of excessive keratin in hyperkeratotic skin disorders.

These products have been internally developed by scientists at IGI and will be independently marketed by a pharmaceutical company. The commercial manufacturing is expected to commence in fourth quarter 2008.

"Successful launch of these products, by our customer, will be an important milestone in the history of our company and will qualify us as a service provider to pharmaceutical companies engaged in sales and marketing of prescription products. This is in line with our initiative to internally develop pharmaceutical products and partner with pharmaceutical companies to bring the products to market," stated Rajiv Mathur, President and CEO of the company.

About IGI

IGI is a company committed to growth by applying proprietary technologies to achieve cost-effective solutions for varied customer needs. IGI offers the patented Novasome micro-vesicular delivery technology which contributes value-added qualities to cosmetics, skin care products, dermatological formulations and other consumer products, providing improved dermal absorption, controlled and sustained release as well as improved stability and greater ease of formulation.

This report contains forward-looking statements relating to IGI's hopes and expectations for the future. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "will," "possible," "one time," "provides an opportunity," "continue" and similar expressions are intended to identify forward-looking statements. Such statements involve a number of risks and uncertainties and actual future events and results could differ materially from those indicated by such forward-looking statements due to general economic conditions, and the risk factors detailed in IGI's periodic reports and registration statements filed with the Securities and Exchange Commission.

Copyright 2008 Business Wire All Rights Reserved.